ARTICLE | Company News
Biogen Idec, ImmunoGen TAP deal
October 6, 2004 7:00 AM UTC
BIIB received exclusive worldwide rights to develop and commercialize IMGN's maytansinoid tumor-activated prodrug (TAP) linked with BIIB's antibodies against an undisclosed tumor cell target. Maytansi...